SFP
CLDX icon

Santa Fe Partners’s Celldex Therapeutics CLDX Stock Holding History

Santa Fe Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,102
Closed -$1.72M – 495
2015
Q1 		$1.72M Buy
4,102
+534
+15% +$191K 0.21% 214
2014
Q4 		$977K Buy
+3,568
New +$887K 0.12% 297

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Santa Fe Partners's CLDX Position: Q2 2015 in Review

Santa Fe Partners sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 4,102 shares — an estimated $1.72M sold.

Santa Fe Partners first reported a position in CLDX in Q4 2014 and held it in 2 quarters. The position peaked at $1.72M in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

  • Santa Fe Partners reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Santa Fe Partners sold 4,102 Celldex Therapeutics shares in Q2 2015, an estimated $1.72M.
  • Santa Fe Partners first reported a position in Celldex Therapeutics in Q4 2014 and held it in 2 quarters.
  • Santa Fe Partners's Celldex Therapeutics position peaked at $1.72M in Q1 2015.
  • 186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on Santa Fe Partners's 13F filing for Q2 2015, filed 13 Aug 2015.